<DOC>
	<DOCNO>NCT00056147</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness multiple dosage INS37217 compare placebo 28 day subject mild moderate cystic fibrosis ( CF ) lung disease . Study drug administer nebulizer ( device delivers medication mist breathing ) .</brief_summary>
	<brief_title>Study INS37217 Inhalation Solution Mild Moderate Cystic Fibrosis Lung Disease</brief_title>
	<detailed_description>The purpose study : - ass safety efficacy multiple dose level INS37217 compare placebo 28 day subject mild moderate CF lung disease ; - explore evidence activity INS37217 placebo administer via PARI LC STAR nebulizer ; - identify dose ( ) study subsequent trial .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<criteria>confirm diagnosis CF FEV1 great equal 75 % predict normal age , gender , height oxyhemoglobin saturation great equal 90 % clinically stable abnormal renal liver function clinically significant finding atypical moderate cystic fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>cystic fibrosis</keyword>
</DOC>